Syndrome of Inappropriate Antidiuretic Hormone after vinorelbine treatment

J Oncol Pharm Pract. 2013 Dec;19(4):380-3. doi: 10.1177/1078155212473003. Epub 2013 Jan 24.

Abstract

Background: Among oncologic patients, Syndrome of Inappropriate Antidiuretic Hormone is a common cause of hyponatremia, a prevalent electrolyte disorder. There are many causes for Syndrome of Inappropriate Antidiuretic Hormone, including chemotherapy medications. To date, only three cases associating vinorelbine and Syndrome of Inappropriate Antidiuretic Hormone have been published.

Case: A 47-year-old woman with stage IIIC serous ovarian adenocarcinoma developed life-threatening hyponatremia (124 mmol/L) after three cycles of vinorelbine. Assessment revealed Syndrome of Inappropriate Antidiuretic Hormone as the most likely culprit. Conservative managements including free fluid restriction normalized her sodium level and Syndrome of Inappropriate Antidiuretic Hormone resolved after vinorelbine discontinuation.

Conclusion: Vinorelbine can cause Syndrome of Inappropriate Antidiuretic Hormone. It is important to monitor sodium concentration during vinorelbine treatment to avoid serious neurological complications of hyponatremia and to improve patient's quality of life.

Keywords: Syndrome of Inappropriate Antidiuretic Hormone; ovarian cancer; vinorelbine.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents, Phytogenic / adverse effects*
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Cystadenocarcinoma, Serous / drug therapy
  • Cystadenocarcinoma, Serous / pathology
  • Female
  • Humans
  • Inappropriate ADH Syndrome / chemically induced*
  • Middle Aged
  • Neoplasm Staging
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / pathology
  • Quality of Life
  • Sodium / blood
  • Vinblastine / adverse effects*
  • Vinblastine / analogs & derivatives
  • Vinblastine / therapeutic use
  • Vinorelbine

Substances

  • Antineoplastic Agents, Phytogenic
  • Vinblastine
  • Sodium
  • Vinorelbine